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Purpose: Mechanical closure devices for arterial hemostasis after angiography, such as the Perclose suture-mediated closure
system, are designed to decrease time to ambulation and improve patient comfort. Although these devices are safe and
efficacious, to date there has been little reported about use of the Perclose device in a cohort consisting exclusively of
patients with lower extremity peripheral vascular disease. The purpose of this study was to determine the safety and
efficacy of routine use of the Perclose system in patients with documented peripheral vascular disease undergoing
angiography to treat chronic lower extremity ischemia.
Methods: The Perclose device was placed for arterial closure after femoral artery access in 500 consecutive patients with
documented peripheral vascular disease (ankle-brachial index, <0.8) who underwent diagnostic angiography or percu-
taneous intervention because of chronic lower extremity ischemia. These 500 patients composed 91% of all patients who
underwent angiography because of chronic lower extremity ischemia between January 1, 2001, and April 1, 2002. All
complications associated with the Perclose device were identified and reviewed.
Results: Of the 500 arteries, 54% were accessed for diagnostic angiography and 46% for intervention. Perclose device
placement was successful in 475 attempts (95%). Overall major complication rate was 1.4% (7 of 500 arteries).
Complications included one death from retroperitoneal hemorrhage; three episodes of limb ischemia, two requiring
operation and one requiring lytic therapy; two pseudoaneurysms; and one hematoma, which prolonged hospitalization.
The hematoma was the only complication in the 25 patients with failed Perclose device placement. There were no
infections requiring admission or operation.
Conclusion: The Perclose suture-mediated closure device is efficacious and can be used safely in selected patients with
documented peripheral vascular disease. Complications associated with this device tend to be more severe than those
historically reported for manual compression. Substantial experience with use of this device is required to achieve
excellent results in patients with difficult anatomy. (J Vasc Surg 2003;38:1305-8.)
Hemostasis after arterial access for diagnostic angiog-
raphy or percutaneous intervention has traditionally been
achieved with manual compression of the punctured artery.
In an attempt to improve patient comfort and to decrease
time to ambulation, several types of arterial closure devices
have been developed. In several studies the Perclose suture-
mediated closure device (Perclose, Redwood City, Calif)
was effective and safe for achieving arterial hemostasis after
diagnostic and therapeutic angiography.1-5 Most of these
studies were in patients undergoing cardiac catheteriza-
tion.1,2,4,5 The goal of the present study was to determine
the safety and efficacy of the Perclose system in a patient
population undergoing angiography or percutaneous inter-
vention solely for diagnosis and treatment of chronic lower
extremity ischemia.
METHODS
Study population. From January 1, 2001, to April 1,
2002, 500 consecutive patients who received a Perclose
suture-mediated closure device after diagnostic angiogra-
phy or percutaneous intervention because of chronic lower
extremity ischemia were identified. Patient data were retro-
spectively retrieved from a prospectively collected comput-
erized registry, and were reviewed regarding success of
device deployment and indications for the procedure. All
major complications were examined to identify any poten-
tially associated with use of the Perclose device.
Chronic lower extremity ischemia was classified as ei-
ther claudication, defined by clinical impression, with asso-
ciated ankle-brachial index less than 0.8 at rest or after
exercise, or as limb-threatening ischemia, defined as rest
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pain, foot ulcer or gangrene, with associated ankle-brachial
index less than 0.5.
Successful device deployment was defined as complete
arterial hemostasis without need for extended additional
manual compression. Successful device deployment was
still reported if manual compression was necessary for only
a short time (2 minutes) to stop the minimal venous
bleeding that may occur just after the procedure is com-
pleted.
A major complication was defined as an event that
required either repeat intervention, operation, admission
for 24 hours or longer compared with that initially planned,
blood transfusion, or intravenous antibiotic therapy. Small
hematomas and skin ecchymoses not requiring transfusion
or prolonged admission were not listed as major complica-
tions.
Exclusion criteria. To develop a patient population as
homogenous as possible, all patients with acute exacerba-
tion of chronic lower extremity ischemia and all patients
who underwent thrombolysis as part of the intervention
were excluded from the study. We routinely use the Per-
close suture-mediated closure device in such patients. It
was concluded that several factors inherent in these pa-
tients, such as extended sheath insertion time in patients
undergoing lysis and the higher percentage of such patients
who require emergent surgery, might bias the results of the
study and shift focus away from those patients that the
study was primarily designed to include. Additional exclu-
sion criteria included aneurysmal disease and brachial artery
access rather than common femoral artery access for
arteriography.
Procedure. The 6F (Closer) device and the 8F and
10F (Prostar) devices were used in the study. These devices
function through placement of two or four suture-bearing
needles through the arterial wall around the puncture site.
After removal of the arterial sheath the device is tracked
over the diagnostic guide wire into the artery. Accurate
depth of the device is confirmed with pulsatile blood return
from the device marker lumen. The needles are then de-
ployed through the artery. The sutures are tied by hand or
with a knot-tying device. Once the knot is preliminarily tied
above the skin level, the device is removed and the knot is
cinched down onto the artery. This closes the arteriotomy
and achieves hemostasis. The remaining free suture is then
cut just above the knot, and a dressing is placed on the
wound. All patients who received a Perclose device in this
study were required to remain supine in bed for 2 hours. All
patients in whom Perclose placement failed were kept in
bed for a minimum of 6 hours after 20 minutes of manual
compression.
All physicians involved in the study had substantial
experience with use of the Perclose device before the study.
All patients who underwent diagnostic angiography or
percutaneous intervention with a femoral artery approach
were considered for placement of a Perclose device. In
general, approximately 91% of patients (500 of 550) who
underwent angiography received a Perclose device at the
end of the procedure. Reasons for not placing a Perclose
device included imminent open bypass procedure with the
punctured femoral artery as an inflow or outflow vessel,
puncture that was believed to be too close to the femoral
bifurcation for safe placement of a closure device, presence
of a bypass graft sewed to the punctured femoral artery, and
physician judgment that there was too much scarring in the
groin accessed or calcification in the artery punctured to
safely allow placement of a closure device. These factors are
relative contraindications to use of a Perclose device. All
patients received pre-procedure antibiotic therapy, and all
patients who underwent intervention received peri-proce-
dure heparin and post-procedure antiplatelet therapy.
RESULTS
Of 500 arterial procedures, 270 arteries (54%) were
accessed for diagnostic angiography and 230 arteries (46%)
were accessed for an interventional procedure. The right
common femoral artery was more commonly accessed
(60%) than the left common femoral artery (40%). Of the
230 arteries accessed for an interventional procedure, 52%
involved aortiiliac occlusive disease and 48% involved in-
frainguinal atherosclerotic vascular disease. Sheath size
ranged from 5F to 10F, with 5F the most common size
(64%). The most commonly placed Perclose device was the
6F Closer device (73%).
Placement of the Perclose device was successful in 475
of 500 (95%) attempts. In the 25 arteries in which the
attempt failed, manual compression was used to attain
arterial hemostasis in 21 patients and an alternative arterial
closure device was used in 4 patients. Of the 25 patients
with failed Perclose device placement, 15 attempts failed as
a result of inability to deliver the device into the artery
secondary to presence of scar tissue (n  12) or heavy
calcification (n  3). In four patients the device did not
deploy as expected, with difficulty in needle deployment or
a question of device fracture. In the remaining six patients
the device was deployed, but successful hemostasis was not
achieved, and additional manual compression was neces-
sary.
Seven major complications occurred, for an overall rate
of 1.4% (7 of 500). Complications included one death
secondary to retroperitoneal hemorrhage. Three patients
had ipsilateral lower extremity ischemic events; surgical
intervention was required in two of these patients, and lysis
was necessary in one patient. The two patients who re-
quired surgical intervention to treat ischemia had bypass
grafts originating from the common femoral artery in the
groin in which the Perclose device was placed. Deployment
of the device caused occlusion of the femoral artery, which
required surgical intervention in both patients. Two
pseudoaneurysms were identified; one warranted a surgical
procedure, and one was managed with thrombin injection.
Post-procedure hematoma in a single patient was the only
complication that occurred in the 25 patients with failed
Perclose placement. In five of seven patients with compli-
cations, arteries had been previously accessed or surgically
exposed. No patients in the study group required readmis-
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sion to the hospital or surgery because of groin infection
after placement of a Perclose device.
DISCUSSION
Arterial closure devices for arterial hemostasis have
been developed in response to the quickly growing field of
percutaneous therapy for both coronary and peripheral
arterial occlusive disease. Most of these procedures are
performed with common femoral artery access. Hemostasis
at the access site with manual compression is uncomfort-
able for the patient and requires prolonged bed rest. Clo-
sure devices are designed to increase patient comfort and
decrease time to ambulation. Suture-mediated devices are
designed to mechanically close the arteriotomy site with
placement of a stitch through the arterial wall. Manufactur-
ing guidelines recommend that these devices not be used in
the setting of significant femoral arterial occlusive or calcific
disease.6 Most studies of the safety and efficacy of these
devices have been in patients with coronary artery disease
who have undergone cardiac catheterization.1-4 The
present study examined a patient population with chronic
lower extremity ischemia who underwent diagnostic or
therapeutic angiography. The goal of this review was to
determine whether routine use of a suture-mediated clo-
sure device in this patient population could be accom-
plished efficaciously, with acceptable morbidity and mor-
tality.
Successful deployment of the Perclose device was
achieved in 95% of patients. This rate is consistent with rates
reported in patients without documented peripheral vascu-
lar disease.1-5 In patients in whom placement attempts
failed, inability to guide the delivery system into the artery
was the most common reported problem. This difficulty is
often encountered in vessels that have been previously
accessed or surgically exposed. In our opinion, an aggres-
sive approach toward Perclose device deployment in this
group of patients requires substantial experience in use of
these devices to avert a high complication rate. Of interest
is that in the 25 patients with failed Perclose device place-
ment there was only one complication. On the basis of
these results, it appears that hemostasis can still be achieved
safely after a failed attempt to place a Perclose device.
The overall 1.4% major complication rate is similar to
that in previous reports involving patients in whom arteries
were accessed for reasons other than chronic lower extrem-
ity ischemia.1-4 Two of seven patients in whom a compli-
cation occurred had a graft anastomosis to the femoral
artery that was punctured. Difficulty with identification of
the exact location of the hood of a graft in relation to the
site of arterial puncture should make one hesitant to place a
suture-mediated closure device.
None of the patients in this study had a major groin
infection after Perclose placement. That all patients were
given a single dose of intravenous antibiotic before the
procedure may be a contributing factor. Although the
incidence of infection after placement of a Perclose device
has been low,7,8 the reported major consequences of such
infection7-9 may be sufficient indication for pre-procedure
antibiotic therapy.
Although this study included 500 consecutive patients
who received a Perclose device after arteriography because
of lower extremity ischemia, not every patient who under-
went arteriography because of lower extremity ischemia
during the study period underwent an attempt at place-
ment of a Perclose device. Placement of a Perclose device
was at the discretion of the physician. Approximately 9% of
patients (50 of 550 consecutive patients) who underwent
angiography or percutaneous intervention with a femoral
artery approach did not receive a Perclose device. Reported
reasons included presence of a bypass graft in the groin
accessed for the procedure, severe groin scarring, puncture
site thought too close to the femoral bifurcation for safe
closure device placement, severe calcification, or reluctance
to place a Perclose into an artery in a patient who was
scheduled to undergo imminent bypass grafting with use of
the femoral artery as the inflow or outflow vessel. Selection
of the patient population reviewed may have improved our
results, because the Perclose device was not placed in those
patients whom the clinicians believed had little chance for
successful device deployment or who were most at risk for
complications.
The results of this study show that the Perclose suture-
mediated closure device is effective and can be used safely in
selected patients with documented peripheral vascular dis-
ease. We also found that use of the Perclose device in our
patients improved patient comfort and shortened time to
ambulation and discharge. Aggressive use in patients with
scarred groins or heavily calcified arteries is best reserved for
clinicians with extensive experience in deployment of these
devices. We define extensive experience as 10 or more
device deployments in normal arteries or 30 deployments in
anatomically difficult arteries or scarred groins. It must also
be emphasized that complications associated with this de-
vice often are more severe than those associated with man-
ual compression. In this study, three of seven patients with
complications required repeat interventions, and one pa-
tient died. Caution is particularly required when consider-
ing use of a suture-mediated closure device when the
accessed femoral artery has a bypass graft anastamosis,
unless imaging studies clearly demonstrate that the arterial
puncture site is remote to the bypass graft hood. Pre-
procedure antibiotic therapy and careful attention to sterile
technique may help minimize potentially devastating infec-
tious complications.
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